EASL Studio is a weekly digital initiative that brings together leading experts in liver disease and research. Through live broadcasts, the programme features engaging interviews, debates, and roundtable discussions on multidisciplinary topics in hepatology for all those with an interest in the liver, no matter their location.
Designed to provide knowledge and expert perspectives, EASL Studio keeps the medical and scientific community informed on the latest advancements. Special live editions are hosted during EASL Congresses and Summits, delivering key messages on the latest science in clinical practice, prevention, and patient care.
All previous episodes can be accessed on-demand on EASL Campus.
Next episodes
8 October
Season 9, Episode 5 - Does it really matter whether we call it ACLF or acute decompensation? (Live from 18:00 CET)
5 November
Season 9, Episode 6 - Are we finally entering an era of effective treatment for PSC? (Live from 18:00 CET)
October 2025
| 1 October
18:00 CEST |
The Clinical Blind Spot: Are We Neglecting Alcohol?
Maja Thiele (Moderator), Brian Lee (Faculty), Mzamo Mbelle (Faculty), Elisa Pose (Faculty) |
| 8 October
18:00 CEST |
Does it really matter whether we call it ACLF or acute decompensation?
Tom Marjot (Moderator), Paolo Angeli (Faculty), Julia Wendon (Faculty)
This EASL Studio is supported by GENFIT. EASL has received no input from GENFIT with regards to the content of this programme. |
November 2025
| 5 November
18:00 CET |
Are we finally entering an era of effective treatment for PSC?
Debbie Shawcross (Moderator), Cynthia Levy (Faculty), Stephen Rossi (Faculty), Michael Trauner (Faculty) |
| 12 November
18:00 CET |
Behind the Decision: How Can You Maximize Your Chances of Publication in JHEP Reports?
Mattias Mandorfer (Moderator), Tobias Böttler (Faculty), Virginia Hernández-Gea (Faculty), Josep Llovet (Faculty) |
| 19 November
18:00 CET |
MASLD in Practice: Who to Treat, With What, and for How Long?
Cyrielle Caussy (Moderator), Maru Rinella (Madrigal Representative), Jörn Schattenberg (Boehringer Ingelheim Representative)
This EASL Studio is supported by Madrigal, NovoNordisk, and Boehringer Ingelheim. |
| 26 November
18:00 CET |
Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance
Debbie Shawcross (Moderator), Rajiv Jalan (Faculty), Vish Patel (Faculty), Jonel Trebicka (Faculty) |
December 2025
| 3 December
18:00 CET |
Decoding AASLD The Liver Meeting: Trends Shaping Hepatology
Debbie Shawcross (Moderator), Saul Karpen (Faculty), Mazen Nourreddin (Faculty) |
| 10 December
18:00 CET |
What Can Be Done to Safeguard Young Adults from SLD?
Shira Zelber Sagi (Moderator), Faculty to be confirmed soon |
| 17 December
18:00 CET |
Collaborating across disciplines to find the best solution for people living with PBC
Cynthia Levy (Moderator), Marco Carbone (Faculty), Bettina Hansen (Faculty), David Jones (Faculty) |
Discover the EASL Studio Policy Dialogues
